{"id":29496,"date":"2023-06-05T11:37:48","date_gmt":"2023-06-05T01:37:48","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=29496"},"modified":"2023-06-15T08:47:59","modified_gmt":"2023-06-14T22:47:59","slug":"prescient-therapeutics-shareholder-replay-8th-june-2023","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/","title":{"rendered":"Prescient Therapeutics Shareholder Replay 8th June 2023"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmdc08b6b gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm055e3d8\" class=\"wp-block-gutentor-m4 section-gm055e3d8 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm58c32e\" class=\"wp-block-gutentor-m4-col col-gm58c32e gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm58c32e\" class=\"section-gm58c32e gutentor-col-wrap\">\n<h2 class=\"has-text-align-center has-white-color has-text-color wp-block-heading\" style=\"font-size:33px\">Prescient Therapeutics: Cell Therapies presentations from ISCT<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmc6b1215\" class=\"wp-block-gutentor-m4 section-gmc6b1215 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmd3302e\" class=\"wp-block-gutentor-m4-col col-gmd3302e gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmd3302e\" class=\"section-gmd3302e gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/06\/Frame-662.png\" alt=\"\" class=\"wp-image-29536\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/06\/Frame-662.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/06\/Frame-662-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/834291075?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm618afc\" class=\"wp-block-gutentor-m4-col col-gm618afc gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm618afc\" class=\"section-gm618afc gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\"><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Prescient Therapeutics held a special Cell Therapies briefing to discuss data presented at the prestigious International Society of Cell &amp; Gene Therapy (ISCT) conference in Paris in June 2023.<br><br>CEO and MD of Prescient Therapeutics, Steven Yatomi-Clarke, Senior VP of Scientific Affairs at Prescient, Dr Rebecca Lim, and post-doctoral scientist at the Peter MacCallum Cancer Centre, Dr Kevin Sek, discussed:<\/p>\n\n\n\n<ul class=\"white wp-block-list\"><li>Prescient\u2019s next-gen modular, controllable CAR platform, OmniCAR.<\/li><li>Clinic-ready cell therapy enhancement platform, CellPryme.<\/li><li>How these cell therapy technologies overcome the limitations of existing and emerging cell therapies.<\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 8th June 2023 at 12:00pm (AEST)<br><br><a rel=\"noreferrer noopener\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/cell-therapies-presentations-from-isct\/\" target=\"_blank\">View the posters presented at ISCT<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gmd3cbbb4 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"speak has-text-color wp-block-heading\" style=\"color:#ffcc00\">Featured Speakers<\/h4>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\"><\/h3>\n\n\n\n<section id=\"gm70baf08\" class=\"wp-block-gutentor-m4 section-gm70baf08 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm14875e\" class=\"wp-block-gutentor-m4-col col-gm14875e gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gm14875e\" class=\"section-gm14875e gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmb80d8c\" class=\"wp-block-gutentor-m4-col col-gmb80d8c gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gmb80d8c\" class=\"section-gmb80d8c gutentor-col-wrap\">\n<figure class=\"wp-block-image size-large speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped-1024x1024.jpg\" alt=\"\" class=\"wp-image-29487\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped-1024x1024.jpg 1024w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped-300x300.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped-150x150.jpg 150w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped-768x768.jpg 768w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Rebecca-Lim-cropped.jpg 1398w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Dr Rebecca Lim<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">Senior Vice President of Scientific Affairs at Prescient Therapeutics<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmd4888d\" class=\"wp-block-gutentor-m4-col col-gmd4888d gutentor-single-column  grid-lg-4 grid-md-12 grid-12\"><div id=\"section-gmd4888d\" class=\"section-gmd4888d gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"800\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Dr-Kevin-Sek.jpeg\" alt=\"\" class=\"wp-image-29486\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Dr-Kevin-Sek.jpeg 800w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Dr-Kevin-Sek-300x300.jpeg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Dr-Kevin-Sek-150x150.jpeg 150w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/05\/Dr-Kevin-Sek-768x768.jpeg 768w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/figure>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Dr Kevin Sek<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">Postdoctoral Researcher at Peter MacCallum Cancer Centre<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr Kevin Sek is a postdoctoral researcher at the Peter MacCallum Cancer Centre. He has conducted extensive research into enhancing CAR-T therapies and previously undertook postdoctoral research with Prescient Therapeutics.<\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":38,"featured_media":29204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-29496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-05T01:37:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T22:47:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adrian Montesano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrian Montesano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\"},\"author\":{\"name\":\"Adrian Montesano\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"headline\":\"Prescient Therapeutics Shareholder Replay 8th June 2023\",\"datePublished\":\"2023-06-05T01:37:48+00:00\",\"dateModified\":\"2023-06-14T22:47:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\"},\"wordCount\":278,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\",\"name\":\"Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"datePublished\":\"2023-06-05T01:37:48+00:00\",\"dateModified\":\"2023-06-14T22:47:59+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Shareholder Replay 8th June 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\",\"name\":\"Adrian Montesano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"caption\":\"Adrian Montesano\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/","og_site_name":"PTX Therapeutics","article_published_time":"2023-06-05T01:37:48+00:00","article_modified_time":"2023-06-14T22:47:59+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","type":"image\/png"}],"author":"Adrian Montesano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrian Montesano","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/"},"author":{"name":"Adrian Montesano","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"headline":"Prescient Therapeutics Shareholder Replay 8th June 2023","datePublished":"2023-06-05T01:37:48+00:00","dateModified":"2023-06-14T22:47:59+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/"},"wordCount":278,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/","name":"Prescient Therapeutics Shareholder Replay 8th June 2023 - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","datePublished":"2023-06-05T01:37:48+00:00","dateModified":"2023-06-14T22:47:59+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/02\/ptx.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-shareholder-replay-8th-june-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Shareholder Replay 8th June 2023"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6","name":"Adrian Montesano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","caption":"Adrian Montesano"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=29496"}],"version-history":[{"count":17,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29496\/revisions"}],"predecessor-version":[{"id":30095,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/29496\/revisions\/30095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/29204"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=29496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=29496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=29496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}